Terns Pharmaceuticals, Inc. (TERN)
NASDAQ: TERN · Real-Time Price · USD
42.12
+1.20 (2.93%)
At close: Feb 27, 2026, 4:00 PM EST
42.24
+0.12 (0.28%)
After-hours: Feb 27, 2026, 7:05 PM EST
Terns Pharmaceuticals Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Terns Pharmaceuticals stock have an average target of 48.6, with a low estimate of 7.44 and a high estimate of 60. The average target predicts an increase of 15.38% from the current stock price of 42.12.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 11, 2025.
Analyst Ratings
The average analyst rating for Terns Pharmaceuticals stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 1 | 3 | 3 | 3 | 3 |
| Buy | 3 | 4 | 6 | 6 | 6 | 6 |
| Hold | 3 | 3 | 2 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 8 | 11 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens | Citizens | Buy Maintains $35 → $57 | Buy | Maintains | $35 → $57 | +35.33% | Dec 11, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $35 → $56 | Strong Buy | Maintains | $35 → $56 | +32.95% | Dec 9, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $28 → $58 | Buy | Maintains | $28 → $58 | +37.70% | Dec 9, 2025 |
| BMO Capital | BMO Capital | Buy Maintains $35 → $54 | Buy | Maintains | $35 → $54 | +28.21% | Dec 9, 2025 |
| Barclays | Barclays | Buy Maintains $36 → $56 | Buy | Maintains | $36 → $56 | +32.95% | Dec 9, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.11
from -1.12
EPS Next Year
-1.21
from -1.11
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.06 | -0.84 | ||||
| Avg | -1.11 | -1.21 | ||||
| Low | -1.17 | -1.51 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.